|
|
|
|
| LEADER |
00000cam a2200000 7i4500 |
| 001 |
0000091753 |
| 005 |
20170828093000.0 |
| 008 |
170530s2015 gw eng |
| 020 |
|
|
|a 9783527335114
|
| 020 |
|
|
|a 9783527673643
|
| 020 |
|
|
|a 9783527673650
|
| 020 |
|
|
|a 9783527673667
|
| 020 |
|
|
|a 9783527673674
|
| 050 |
0 |
0 |
|a RS420
|b .A58 2015
|
| 060 |
1 |
0 |
|a QV 600
|b .A629 2015
|
| 090 |
0 |
0 |
|a RS420
|b .A58 2015
|
| 245 |
0 |
0 |
|a Antitargets and drug safety
|c edited by Laszlo Urban, Vinod F. Patel, Roy J. Vaz
|
| 260 |
|
|
|a Weinheim, Germany :
|b Wiley-VCH ,
|c c2015
|
| 300 |
|
|
|a Vol. 66, xxv, 497 p. :
|b ill. (some col.) ;
|c 25 cm.
|
| 440 |
|
|
|a Methods and principles in medicinal chemistry
|v v. 66
|
| 504 |
|
|
|a Includes bibliographical references and index
|
| 505 |
0 |
|
|a 1. Side effects of marketed drugs: the utility and pitfalls of pharmacovigilance -- 2. In silico prediction of drug side effects -- 3. Translational value of preclinical safety assessment: system organ class (SOC) representation of off-targets -- 4. Pathological conditions associated with the disturbance of the 5-HT system -- 5. Drug-induced liver injury: clinical and diagnostic aspects -- 6. Mechanistic safety biomarkers for drug-induced liver injury -- 7. In vitro models for the prediction of drug-induced liver injury in lead discovery -- 8. Transporters in the liver -- 9. Mechanistic modeling of drug-induced liver injury (DILI) -- 10. Functional cardiac safety evaluation of novel therapeutics -- 11. Safety aspects of the Cav1.2 channel -- 12. Cardiac sodium current (Nav1.5) -- 13. Circulating biomarkers for drug-induced cardiotoxicity: reverse translation from patients to nonclinical species -- 14. The mechanistic basis of hERG blockade and the proarrhythmic effects thereof -- 15. Introduction to kinase antitargets -- 16. Clinical and nonclinical adverse effects of kinase inhibitors -- 17. Cardiac side effects associated with kinase proteins and their signaling pathways -- 18. Case studies: selective inhibitors of protein kinases exploiting demure features -- 19. Torcetrapib and dalcetrapib safety: relevance of preclinical In vitro and In vivo models -- 20. Targets associated with drug-related suicidal ideation and behavior
|
| 650 |
|
0 |
|a Drug development
|
| 650 |
|
0 |
|a Drugs
|x Design
|
| 650 |
|
0 |
|a Drugs
|x Side effects
|
| 700 |
1 |
|
|a Patel, Vinod F. ,
|e author
|
| 700 |
1 |
|
|a Urban, Laszlo ,
|d 1951- ,
|e author
|
| 700 |
1 |
|
|a Vaz, Roy J. ,
|e author
|
| 999 |
|
|
|a 1000169198
|b Book
|c OPEN SHELF (30 DAYS)
|e Tembila Campus
|